Avesina Hearing Revenue and Competitors

Smørum,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Avesina Hearing's estimated annual revenue is currently $1.5B per year.(i)
  • Avesina Hearing's estimated revenue per employee is $251,000

Employee Data

  • Avesina Hearing has 5822 Employees.(i)
  • Avesina Hearing grew their employee count by 6% last year.

Avesina Hearing's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is Avesina Hearing?

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect and communicate with the world around them. For more than a century, the Demant Group has played a vital part in developing innovative technologies and know-how to help improve people's hearing and health. In every aspect, from hearing devices, hearing implants and diagnostic equipment to hearing care all over the world, Demant is active and engaged. A growing business in intelligent audio solutions for gaming and office communication is also a significant part of the Group. The Demant Group operates in a global market with companies in more than 30 countries, employs more than 14,500 staff and generates annual revenue of DKK 14 billion. Our products are sold in more than 130 countries where we create life-changing differences through hearing health. Listed on the Nasdaq Copenhagen stock exchange as one of the 25 most traded shares in terms of free floated market capitalisation, also known as the C25 index, Demant is the parent company behind the commercial successes of such world-renowned brands as Oticon, Bernafon, Sonic, Audika, Oticon Medical, MAICO, Interacoustics, Amplivox, Grason-Stadler, MedRx and Sennheiser Communications. William Demant Invest A/S, a company wholly owned by William Demant Foundation, holds the majority of shares in Demant A/S, providing stability and strength for the long haul.

keywords:N/A

N/A

Total Funding

5822

Number of Employees

$1.5B

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Avesina Hearing News

2022-04-17 - CRISPR Technology Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

... COVID-19” published in Avicenna Journal of Medical Biotechnology ... first-in-human clinical trial of a CRISPR gene correction therapy...

2022-04-17 - Class notes: Spring 2022 - News - Illinois State

Mark Reppen '15, '19, is a deaf and hard-of-hearing teacher at Lemont High ... Mary (Radavic) Maiellaro '16, is employed with Avicenna...

2022-03-22 - Another Biogen-Ionis collab hits the dust after phase 1 ALS flop

The study recruited 106 trial participants with C9orf72-gene-associated ALS and divided them into six ... Viz.ai upgrades triage platform with Avicenna.